Yiwu Liuti Trading company

Flibanserin

Density：1.292±0.06 g/cm3(Predicted)
Storage temp.：2-8°C
Solubility DMSO: soluble10mg/mL, clear
Form：powder
Pka：12.12±0.30(Predicted)
Color：white to beige
InChI：InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
InChIKey：PPRRDFIXUUSXRA-UHFFFAOYSA-N
SMILES：C1(=O)N(CCN2CCN(C3=CC=CC(C(F)(F)F)=C3)CC2)C2=CC=CC=C2N1

Flibanserin Usage And Synthesis

Description
Flibanserin (Addyi-Sprout Pharmaceuticals) is a first-in-class oral medication approved by FDA for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Although it meets the need for drugs that address women’s sexual function, flibanserin is unlike agents that treat erectile dysfunction, as it is intended to increase sexual desire, not performance.
Flibanserin is the first prescription medicine for the treatment of this sexual dysfunction. The FDA approval is not without warnings; flibanserin is subject to the Risk Evaluation and Mitigation Strategy (REMS) to ensure safe use by patients, and has a boxed warning directed to prescribing providers. The goal is to inform patients and providers of the increased risk of hypotension and syncope (Vallejos 2017).
Uses:
Filbanserin is an agonist of serotonin-5HT1A receptor and an antagonist of the 5-HT2A receptor. Binds dopamine receptors with Ki values ranging from 4-24 nM. Used to treat hypoactive sexual desire disorder in females.